Jonas Ekblom appointed new Pergamum CEO
(Thomson Reuters ONE) -
STOCKHOLM - October 28, 2010. Jonas Ekblom has been appointed as new Chief
Executive Officer of Pergamum AB, the dermatology and wound healing company in
the Karolinska Development portfolio, from November 1, 2010.
" We are delighted to have attracted Jonas Ekblom, who with his vast experience
from pharmaceutical development will be able to contribute to a continuous
strong development of Pergamum and its programs. Pergamum is a unique biotech
company dedicated to the development of new, innovative treatments within
dermatology and wound healing. Currently, we have a number of promising pre-
clinical projects and three progams undergoing clinical trials" said Jörgen
Thorball, chairman of the board Pergamum AB.
"There is a need for new business models for research and development within the
biotech sector. Pergamum works in a new way; having several companies or
programs within the same therapeutic area in the same organization and using
this to its advantage by offering resources that smaller organizations normally
don't have access to, while at the same time securing the entrepreneurial spirit
needed to drive programs efficiently. I am delighted to take on this role within
Pergamum, says Jonas Ekblom.
Jonas Ekblom has more than 15 years experience from leading positions in big and
small pharmaceutical companies mainly in Sweden and the USA. Most recently, he
has served as CEO at Bows Pharmaceuticals AG, which is a Swiss biotech company.
Before that he was working in the US for several companies, including serving as
head of Invitrogen's project organization between 2005 and 2008. He is also on
the board of the humanitarian non-profit organization "The Releef Initiative"
focused on product development to fulfill unmet needs in under-served areas.
For further information, please contact:
Jörgen Thorball, Chairman of the Board, Pergamum AB
Tel: +46 8-524 891 00, e-mail:jorgen.thorball(at)pergamum.com
TO THE EDITORS
About Pergamum´
Pergamum is a biopharmaceutical company specialized in dermatology and wound
healing. Within Pergamum, companies and projects are managed as fully integrated
operating units with access to a core team of experienced professionals within
drug development and business management. This model provides Pergamum with an
attractive diversified product pipeline, while minimizing development cost and
time-to-market and risk. Three programs are currently in clinical
phase.www.pergamum.com
About Karolinska Development
Karolinska Development manages one of the largest portfolios of life science
companies in Europe. Using a unique business model, the company cost efficiently
guides the commercialization of world class life science innovations. Since its
inception in 2003, Karolinska Development has built a portfolio of some 40
companies. Among the company's projects, 12 candidate drugs are undergoing
clinical trials and it is estimated that more than 20 substances have first-in-
class potential.www.karolinskadevelopment.com
[HUG#1455451]
Jonas Ekblom appointed new Pergamum CEO:
http://hugin.info/143071/R/1455451/396091.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 28.10.2010 - 08:00 Uhr
Sprache: Deutsch
News-ID 46807
Anzahl Zeichen: 0
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 197 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Jonas Ekblom appointed new Pergamum CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
